Eli Lilly has reinforced its partnership with the life sciences-focused venture firm, contributing to its TVM Life Science Innovation II vehicle.
Germany-headquartered venture capital firm TVM Capital Life Science closed its latest vehicle, TVM Life Science Innovation II, at $478m on Tuesday, with pharmaceutical firm Eli Lilly among the limited partners.
The list of backers included undisclosed strategic investors in addition to US-based banks, fund-of-funds, endowments, foundations, pension funds, wealth managers and family offices.
TVM Capital Life Science makes early and late-stage investments in companies developing medical products, diagnostic technology and biopharmaceuticals, in the European Union and North America.
The latest…
